# T Cell Therapy of Opportunistic Cytomegalovirus Infection

> **NCT02982902** · EARLY_PHASE1 · RECRUITING · sponsor: **Mari Dallas** · enrollment: 20 (estimated)

## Conditions studied

- Cytomegalovirus Infections
- Hematopoietic Stem Cell Transplant
- Opportunistic Infections

## Interventions

- **BIOLOGICAL:** CMV specific adoptive t-cells

## Key facts

- **NCT ID:** NCT02982902
- **Lead sponsor:** Mari Dallas
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-05-27
- **Primary completion:** 2027-08
- **Final completion:** 2028-08
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02982902

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02982902, "T Cell Therapy of Opportunistic Cytomegalovirus Infection". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02982902. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*